EANM procedure guideline for (32)P phosphate treatment of myeloproliferative diseases.
(2007) In European Journal of Nuclear Medicine and Molecular Imaging 34(8). p.1324-1327- Abstract
- Introduction P-32 phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom P-32 is the most optimal treatment option, an assertion supported by two large studies with long follow- up. Purpose The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for P-32 phosphate therapy.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/166130
- author
- Tennvall, Jan LU and Brans, Boudewijn
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- nuclear medicine, guidelines, P-32 phosphate, polycythaemia vera, essential thrombocythaemia, radionuclide therapy
- in
- European Journal of Nuclear Medicine and Molecular Imaging
- volume
- 34
- issue
- 8
- pages
- 1324 - 1327
- publisher
- Springer
- external identifiers
-
- wos:000248911800026
- scopus:34548078380
- ISSN
- 1619-7070
- DOI
- 10.1007/s00259-007-0407-4
- language
- English
- LU publication?
- yes
- id
- 1c0e6e91-fe31-4298-9032-2e41d1d35bae (old id 166130)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17396258&dopt=Abstract
- date added to LUP
- 2016-04-01 12:10:56
- date last changed
- 2022-03-28 21:23:57
@article{1c0e6e91-fe31-4298-9032-2e41d1d35bae,
abstract = {{Introduction P-32 phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom P-32 is the most optimal treatment option, an assertion supported by two large studies with long follow- up. Purpose The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for P-32 phosphate therapy.}},
author = {{Tennvall, Jan and Brans, Boudewijn}},
issn = {{1619-7070}},
keywords = {{nuclear medicine; guidelines; P-32 phosphate; polycythaemia vera; essential thrombocythaemia; radionuclide therapy}},
language = {{eng}},
number = {{8}},
pages = {{1324--1327}},
publisher = {{Springer}},
series = {{European Journal of Nuclear Medicine and Molecular Imaging}},
title = {{EANM procedure guideline for (32)P phosphate treatment of myeloproliferative diseases.}},
url = {{http://dx.doi.org/10.1007/s00259-007-0407-4}},
doi = {{10.1007/s00259-007-0407-4}},
volume = {{34}},
year = {{2007}},
}